

Product Datasheet

SARS-CoV-2 ORF6 Antibody - BSA Free NBP3-05707

Unit Size: 50 ug

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP3-05707

Updated 11/16/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP3-05707



NBP3-05707**SARS-CoV-2 ORF6 Antibody - BSA Free****Product Information**

Unit Size	50 ug
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Epitope affinity purified
Buffer	PBS (pH 7.2), 10% Glycerol

Product Description

Description	Novus Biologicals Rabbit SARS-CoV-2 ORF6 Antibody - BSA Free (NBP3-05707) is a polyclonal antibody validated for use in WB and ELISA. Anti-SARS-CoV-2 ORF6 Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	43740572
Gene Symbol	ORF6
Species	SARS-CoV-2
Immunogen	Synthetic peptide corresponding to 17 amino acids of ORF6. Exact sequence is proprietary.


Product Application Details

Applications	Western Blot, ELISA
Recommended Dilutions	Western Blot 1:500-1000, ELISA




Images


ORF6 does not antagonize IFN production. (A–E) Calu-3 cells were uninfected or infected with SARS-CoV-2 WT virus or Δ ORF6 virus (MOI of 0.5). At 24 hpi, cells were treated with Sendai virus (SeV) for 8 h as indicated. (A and B) Total RNA was extracted, and induction of IFN- β (A) and IFN- λ 1 (B) was examined by RT-qPCR. Shown is the mean $\pm$ SEM for three independent experiments. The significance was calculated using Kruskal-Wallis test and is indicated by * $P < 0.05$ (ns, not significant). (C) Cell lysates were collected, and the protein expression level was determined by immunoblotting using indicated antibodies. Shown are the representative blots of two independent experiments. (D) Cells were fixed and stained with antibodies against IRF3 and SARS-CoV-2 Spike. Representative images of two independent experiments are shown. (E) Percent of IRF3 translocation in virally infected cells was quantified. Shown is the average percent for six fields of view from two independent experiments. Significance was calculated using an unpaired, two-tailed Student's *t* test (ns, not significant). (F through H) Calu-3 cells were infected with SARS-CoV-2 WT virus or Δ ORF6 virus (MOI of 0.5) for 24 h, followed by treatment of Poly(I:C) for 6 h as indicated. (F and G) mRNA expression of IFN- β (F) and IFN- λ 1 (G) was determined by RT-qPCR and normalized to uninfected cells. Shown are the means $\pm$ SEM for three independent experiments. The significance was calculated using Kruskal-Wallis test (ns, not significant). (H) Immunoblotting was performed to monitor protein expression using indicated antibodies. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/37377442>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



ORF6 does not antagonize IFN production. (A–E) Calu-3 cells were uninfected or infected with SARS-CoV-2 WT virus or Δ ORF6 virus (MOI of 0.5). At 24 hpi, cells were treated with Sendai virus (SeV) for 8 h as indicated. (A and B) Total RNA was extracted, and induction of IFN- β (A) and IFN- λ 1 (B) was examined by RT-qPCR. Shown is the mean $\pm$ SEM for three independent experiments. The significance was calculated using Kruskal-Wallis test and is indicated by * $P < 0.05$ (ns, not significant). (C) Cell lysates were collected, and the protein expression level was determined by immunoblotting using indicated antibodies. Shown are the representative blots of two independent experiments. (D) Cells were fixed and stained with antibodies against IRF3 and SARS-CoV-2 Spike. Representative images of two independent experiments are shown. (E) Percent of IRF3 translocation in virally infected cells was quantified. Shown is the average percent for six fields of view from two independent experiments. Significance was calculated using an unpaired, two-tailed Student's *t* test (ns, not significant). (F through H) Calu-3 cells were infected with SARS-CoV-2 WT virus or Δ ORF6 virus (MOI of 0.5) for 24 h, followed by treatment of Poly(I:C) for 6 h as indicated. (F and G) mRNA expression of IFN- β (F) and IFN- λ 1 (G) was determined by RT-qPCR and normalized to uninfected cells. Shown are the means $\pm$ SEM for three independent experiments. The significance was calculated using Kruskal-Wallis test (ns, not significant). (H) Immunoblotting was performed to monitor protein expression using indicated antibodies. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/37377442>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



SARS-CoV-2 induces immune responses in bystander cells. (A) Calu-3 cells were either uninfected (Uninf.) or infected with SARS-CoV-2 WT virus or Δ ORF6 virus (MOI = 0.5) for 24, 36, or 48 h. Cells were lysed, and the protein expression level was determined by immunoblotting using indicated antibodies. Shown are representative blots of two independent experiments. (B through E) Calu-3 cells were either uninfected or infected with SARS-CoV-2 WT virus or Δ ORF6 virus (MOI of 0.5) for 48 h. Cells were fixed and stained with antibodies against IRF3 (B) or phospho-STAT1 (p-Stat1) (D). Quantification of IRF3 nuclear translocation (C) in panel (B) or p-Stat1 nuclear translocation (E) in panel (D). Graphs show the average percent of nuclear translocation in viral-infected cells or bystander cells for six fields of view collected from two independent experiments. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/37377442>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Li M, Ayyanathan K, Dittmar M et al. SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection mBio 2023-06-28 [PMID: 37377442] (Western Blot)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP3-05707

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP3-05707

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

